Theranostic SPECT/CT Systems
Radiopharmaceutical Therapy (e.g., Prostate Cancer)
CommercialActive
Key Facts
Indication
Radiopharmaceutical Therapy (e.g., Prostate Cancer)
Phase
Commercial
Status
Active
Company
About Mediso
Mediso is an established, privately-held developer of sophisticated hybrid molecular imaging systems for both clinical and preclinical applications. Its core strength lies in integrated platforms like the AnyScan® TRIO (SPECT/CT/PET) and the cryogen-free nanoScan® PET/MRI, with a strategic focus on the growing theranostics and quantitative imaging markets. The company has demonstrated steady growth through product launches, FDA software approvals, and geographic expansion into key Western European and North American markets via subsidiaries and partnerships.
View full company profile